Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marloes Grobben, Karlijn van der Straten, Philip JM Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Brent Appelman, AH Ayesha Lavell, Lonneke A van Vught, Judith A Burger, Meliawati Poniman, Melissa Oomen, Dirk Eggink, Tom PL Bijl, Hugo DG van Willigen, Elke Wynberg, Bas J Verkaik, Orlane JA Figaroa, Peter J de Vries, Tessel M Boertien, Amsterdam UMC COVID-19 S3/HCW study group, Marije K Bomers, Jonne J Sikkens, Roger Le Grand, Menno D de Jong, Maria Prins, Amy W Chung, Godelieve J de Bree, Rogier W Sanders, Marit J van Gils
Formato: article
Lenguaje:EN
Publicado: eLife Sciences Publications Ltd 2021
Materias:
antibodies
SARS-CoV-2
coronavirus
cross-reactivity
vaccine
COVID-19
Medicine
R
Science
Q
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/355bde8c5cd74382bd903bb187245f09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/355bde8c5cd74382bd903bb187245f09

Ejemplares similares